What Does “Reversing Fatty Liver” Actually Mean?

Less fat, less inflammation, and less scarring tell different stories. A new human trial helps explain why the distinction matters.

Bridgett Renee Health | November 13, 2026

“My liver numbers improved.” “My scan showed less fat.” “The inflammation is gone.”

Each can be encouraging news. But do they all mean the liver has completely recovered?

When we read that someone has “reversed fatty liver,” the most useful question is: What improved, and how was it measured? Understanding that question helps us recognize real progress without promising more than the evidence shows.

One phrase, several different outcomes

Fatty liver associated with metabolic problems is now commonly called MASLD, short for metabolic dysfunction-associated steatotic liver disease. MASH is the form involving inflammation and liver-cell injury. Fibrosis means scar tissue. These features can occur together, but researchers measure them separately. [1,2]

Finding	What it can tell us	What it does not establish by itself
Less liver fat on imaging	Fat accumulation has decreased	Inflammation or scarring has disappeared
Lower ALT or AST blood-test results	Markers of liver injury have improved	Significant scarring is absent
MASH resolution on biopsy	Tissue no longer meets the study’s criteria for MASH	All liver fat and scar tissue are gone
Improvement in fibrosis stage	Scarring is graded as less severe	The liver is completely normal or future risk is eliminated

Normal liver enzymes alone cannot rule out clinically significant fibrosis. Clinicians may use blood-based risk scores, liver-stiffness testing, and sometimes biopsy to assess the bigger picture. [2]

What the new human trial found

Results reported November 9, 2026, and published in The Lancet examined efinopegdutide, an investigational weekly injection. This phase 2b trial enrolled 386 adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis; 381 were randomized and received treatment. These participants had moderate-to-advanced scarring, without cirrhosis. [1]

After 52 weeks, MASH resolved without worsening fibrosis in 56–63% of participants across the three efinopegdutide doses, compared with 13% receiving placebo. Fibrosis improved by at least one stage without worsening MASH in 34–52%, compared with 21% receiving placebo. [1]

These were encouraging human results. Nausea, diarrhea, and vomiting occurred, and side effects led some participants to stop treatment. The highest dose did not produce the highest fibrosis response. [1]

Why improvement is different from a proven cure

The trial provides evidence of improvement in liver tissue over one year. It does not establish that this treatment prevents liver failure, liver cancer, transplantation, or death over the long term. Its results also cannot simply be applied to people with cirrhosis or every person with fatty liver. Efinopegdutide remains investigational. [1]

The study’s wording matters: “MASH resolution without worsening fibrosis” is not the same as “all scarring disappeared.” Likewise, “one-stage fibrosis improvement” is not necessarily a return to a normal liver.

For an individual patient, a meaningful follow-up conversation is: “Which part of my liver health has improved, what still needs attention, and how will we monitor it?”

Where everyday liver support fits

Established guidance supports sustainable lifestyle changes. For people with overweight or obesity, gradual weight loss can reduce liver fat and may improve inflammation and scarring. Physical activity can help even without weight loss. Rapid weight loss and malnutrition can worsen liver disease. [3]

A whole-person approach also means keeping diabetes, other metabolic concerns, and medical follow-up in view. Nutrition choices and activity plans should fit the person’s health, abilities, and treatment needs.

Herbs and supplements deserve the same careful evaluation as other interventions. Some can injure the liver; discuss them with a qualified healthcare professional, especially when taking medicines or living with liver disease. [3]

The efinopegdutide trial did not test a liver cleanse, herbal blend, or dietary program. Its findings cannot validate those approaches.

Maurice’s coaching perspective: why liver health matters at BRH

At Bridgett Renee Health, I place a strong emphasis on liver health
when coaching clients through a range of health challenges. In my
experience, it deserves attention as part of a whole-person wellness
plan. My goal is to help clients understand how to support their liver’s
natural functions while addressing the other factors affecting their
health. The liver is a key focus in my coaching philosophy, alongside
individualized support and appropriate medical care.

— Maurice Massey, Founder and Holistic Wellness Coach, Bridgett Renee
Health

This commentary describes Maurice’s coaching perspective, not a finding of the efinopegdutide trial. Liver function cannot be reduced to a general “80–90%” target that predicts recovery across diseases. Commercial liver detoxes and flushes have not been shown to restore liver function or cure disease; some cleansing practices can cause harm. Supporting the liver’s own work is different from demonstrating that a flush removes toxins. [4]

Hope is stronger when it is specific

The liver-health message is hopeful: improvement is possible, and researchers are learning how to measure it more precisely. For readers of The Liver Health Connection, the useful distinction is between supporting liver health, documenting improvement, and demonstrating lasting clinical benefit.

For a foundation in the liver’s everyday roles, explore what your liver actually does.

When reading a headline, ask what changed, which test showed it, and how long the benefit was followed. Those details turn an exciting claim into useful health education.

Educational information only. Bridgett Renee Health provides wellness education and coaching, not diagnosis or medical treatment. Decisions about testing and treatment belong with a qualified healthcare professional.

Sources and research credit

1. Original study: “Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2–3 fibrosis: a phase 2b, randomised, placebo-controlled study.” The Lancet, November 9, 2026. Study DOI. Verification note: The publisher’s full article was inaccessible during preparation. Trial design, response rates, and adverse-event information above were checked against the MSD sponsor report dated November 9, 2026. This is a sponsor-funded drug study; the sponsor’s announcement is not an independent appraisal.
2. Evidence and guideline context: Disease-Modifying Therapies for Metabolic Dysfunction–Associated Steatohepatitis, Table 7: Alignment of International Guidelines and Pathways, NCBI Bookshelf, accessed November 13, 2026.
3. Established lifestyle and supplement-safety context: NIDDK, Treatment for NAFLD & NASH, accessed November 13, 2026. The older page’s medication-approval statement is not used here.
4. Detox and cleansing evidence: NCCIH, “Detoxes” and “Cleanses”: What You Need To Know; Johns Hopkins Medicine, Detoxing Your Liver: Fact Versus Fiction, accessed November 13, 2026.